Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   - « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Castelo, Beatriz
LIBRETTO-531, NCT04211337 / 2019-001978-28: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer	Active, not recruiting	3	291	Europe, Canada, Japan, US, RoW	Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib	Loxo Oncology, Inc., Eli Lilly and Company	Medullary Thyroid Cancer	05/23	02/26
ABIGAIL, NCT04603183 / 2020-001648-24: ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL	Active, not recruiting	2	162	Europe	Abemaciclib, Verzenios, Paclitaxel, Paclitaxel Teva, Letrozole, Fulvestrant	MedSIR, Eli Lilly and Company	Breast Cancer Metastatic	06/24	06/25
NCT05743270: Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN	Withdrawn	2	130	Europe, US, RoW	RP3, CCRT(concurrent chemoradiation therapy), carboplatin and paclitaxel, nivolumab	Replimune Inc., Bristol-Myers Squibb	Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma	03/26	06/26
VB N-02, NCT05018273: Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors	Completed	1	26	Europe, US	VB10.NEO, Atezolizumab, Tecentriq	Nykode Therapeutics ASA, Genentech, Inc., Vaccibody AS	Solid Tumors, Adult	10/24	10/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Castelo, Beatriz
LIBRETTO-531, NCT04211337 / 2019-001978-28: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer	Active, not recruiting	3	291	Europe, Canada, Japan, US, RoW	Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib	Loxo Oncology, Inc., Eli Lilly and Company	Medullary Thyroid Cancer	05/23	02/26
ABIGAIL, NCT04603183 / 2020-001648-24: ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL	Active, not recruiting	2	162	Europe	Abemaciclib, Verzenios, Paclitaxel, Paclitaxel Teva, Letrozole, Fulvestrant	MedSIR, Eli Lilly and Company	Breast Cancer Metastatic	06/24	06/25
NCT05743270: Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN	Withdrawn	2	130	Europe, US, RoW	RP3, CCRT(concurrent chemoradiation therapy), carboplatin and paclitaxel, nivolumab	Replimune Inc., Bristol-Myers Squibb	Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma	03/26	06/26
VB N-02, NCT05018273: Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors	Completed	1	26	Europe, US	VB10.NEO, Atezolizumab, Tecentriq	Nykode Therapeutics ASA, Genentech, Inc., Vaccibody AS	Solid Tumors, Adult	10/24	10/24